Document is current
Any future updates will be listed below
-
Authors
Jenkins, Kurt A https://orcid.org/0000-0003-2834-7068
Park, Miso
Pederzoli-Ribeil, Magali
Eskiocak, Ugur
Johnson, Parker
Guzman, Wilson
McLaughlin, Megan
Moore-Lai, Deborah
O’Toole, Caitlin
Liu, Zhen
Nicholson, Benjamin
Flesch, Veronica
Qiu, Huawei
Clackson, Tim
O’Hagan, Ronan C
Rodeck, Ulrich
Karow, Margaret
O’Neil, Jennifer
Williams, John C https://orcid.org/0000-0002-0522-384X
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04896697 at ClinicalTrials.govnct04896697 at ClinicalTrials.govDocuments that mention this clinical trial
1455 Phase 1 study of XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2024-sitc2024.1455
541 ctDNA as a potential surrogate biomarker for response to combination vilastobart and atezolizumab in heavily pretreated microsatellite stable (MSS) metastatic colorectal cancer (mCRC) (NCT04896697)
https://doi.org/10.1136/jitc-2025-sitc2025.0541
XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer
https://doi.org/10.1136/jitc-2023-007785
1315 Plasma tumor mutational burden (pTMB) enriched for response to vilastobart in combination with atezolizumab in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
https://doi.org/10.1136/jitc-2025-sitc2025.1315
Phase 1/2 study of XTX101, a masked, tumor-selective Fc-modified anti-CTLA4, in patients with advanced solid tumors.
https://doi.org/10.1200/jco.2023.41.16_suppl.e14685
Documents that mention this clinical trial
1455 Phase 1 study of XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2024-sitc2024.1455
541 ctDNA as a potential surrogate biomarker for response to combination vilastobart and atezolizumab in heavily pretreated microsatellite stable (MSS) metastatic colorectal cancer (mCRC) (NCT04896697)
https://doi.org/10.1136/jitc-2025-sitc2025.0541
XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer
https://doi.org/10.1136/jitc-2023-007785
1315 Plasma tumor mutational burden (pTMB) enriched for response to vilastobart in combination with atezolizumab in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
https://doi.org/10.1136/jitc-2025-sitc2025.1315
Phase 1/2 study of XTX101, a masked, tumor-selective Fc-modified anti-CTLA4, in patients with advanced solid tumors.
https://doi.org/10.1200/jco.2023.41.16_suppl.e14685
-
Funding
Funding for this research was provided by:
Xilio Therapeutics, Inc (N/A)
National Institutes of Health (P30CA033572)
- License Information
